Down-Regulation of Platelet Surface CD47 Expression in Escherichia coli O157:H7 Infection-Induced Thrombocytopenia

Ya-Lan Guo*, Dan-Qing Liu*, Zhen Bian*, Chen-Yu Zhang*, Ke Zen*

Institute for Virology, State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Jiangsu, People’s Republic of China

Abstract

**Background:** Platelet depletion is a key feature of hemolytic uremic syndrome (HUS) caused by Shiga toxin-producing Escherichia coli (STEC) infection. The mechanism underlying STEC-induced platelet depletion, however, is not completely understood.

**Methodology/Principal Findings:** Here we demonstrated for the first time that platelet surface expression of CD47 was significantly decreased in C57BL6 mice treated with concentrated culture filtrates (CCF) from STEC O157:H7. STEC O157:H7 CCF treatment also led to a sharp drop of platelet counts. The reduction of cell surface CD47 was specific for platelets but not for neutrophils, monocytes and red blood cells. Down-regulation of platelet surface CD47 was also observed in isolated human platelets treated with O157:H7 CCF. Platelet surface CD47 reduction by O157:H7 CCF could be blocked by anti-CD47 antibody but not anti-CD62 antibody. Down-regulation of platelet surface CD47 was positively correlated with platelet activation and phagocytosis by human monocyte-derived macrophages. Furthermore, the enhanced phagocytosis process of O157:H7 CCF-treated platelets was abolished by addition of soluble CD47 recombinants.

**Conclusions/Significance:** Our results suggest that platelet CD47 down-regulation may be a novel mechanism underneath STEC-induced platelet depletion, and that the interactions between CD47 and its receptor, signal regulatory protein α (SIRPα), play an essential role in modulating platelet homeostasis.

Introduction

Shiga toxin (Stx)-producing Escherichia coli (STEC) have been widely reported to be associated with cases of hemolytic uremic syndrome (HUS) [1,2]. Although thrombocytopenia is a major feature of HUS, the mechanism by which the platelets are depleted in HUS is unclear. Previous studies indicated that platelet activation might be an important factor for thrombocytopenia since expression of platelet-derived products such as platelet factor 4 [3] and soluble P-selectin [4] were elevated during acute HUS. The plasma from patients with HUS also increased aggregation of normal platelets from healthy subjects. As possible causal factor of HUS, Stx1 and Stx2, are representatives of AB class of bacterial exotoxins [5]. For example, Stx can directly bind to human platelets via globotriaosylceramide (Pk antigen) and a novel platelet glycosphingolipid [6], and such binding may contribute to platelet activation and microthrombus formation observed in HUS. The toxin has also been identified in the kidney of HUS patients [7] and is cytotoxic for renal endothelial and epithelial cells [8,9]. Moreover, animal models have reproduced aspects of HUS using wild-type bacteria that produced the toxin [10,11,12] or purified toxin [13,14]. Culture filtrates from STEC were found to induce platelet-aggregating activity [15] although the experiments with purified Shiga toxin showed controversial results in platelet aggregation or P-selection expression [16,17]. HUS-associated Shiga toxins were found to promote endothelial-cell secretion and impair ADAMTS13 cleavage of unusually large von Willebrand factor multimers [18]. Other STEC secreted components such as LPS also play a significant role in developing the aspects of HUS such as platelet activation and thrombocytopenia [19].

Serving as an integrin-associated protein and a self-recognition marker [20,21,22,23], CD47 has been implicated in depletion of apoptotic cells and aging cells [21,24]. Olsson et al [25] previously showed that platelet homeostasis was modulated by platelet CD47 under both normal condition and passive immune thrombocytopenia. The role of interactions between CD47 and its ligand, signal regulatory protein α (SIRPα), in regulating the clearance of platelets or other apoptotic cells by macrophages was also reported previously [26,27,28]. However, the alteration of platelet CD47 expression and its role in STEC infection-induced platelet depletion remains unclear.
In the present study, we demonstrate that platelet surface CD47 expression is specifically reduced in mice treated with concentrated STEC O157:H7-secreted products (CCF) and the effect of O157:H7 CCF is likely toll-like receptor (TLR)-dependent. Down-regulation of platelet CD47 is positively correlated with an increase of platelet activation and aggregation, as well as the phagocytosis of platelets by macrophages.

**Materials and Methods**

**Bacterial Strains and Reagents**

HEPEC O157:H7 (strain 99G144) was derived from an outbreak of hemolytic-uremic syndrome (HUS) in Xuzhou, Jiangsu, China in 1999. Toxin-negative *E. coli* O157:H19 (strain 99A041) was used as a control [29]. STEC isolates were serotyped using antisera against *E. coli* O antigens 1 to 173 and H antigens 15 to 56. PCR results against four major virulence genes and *hly* have demonstrated that strain 99G144 is a *Stx2-eaeA-hly* type strain, while strain 99A041 is negative for signs of *Stx1, Stx2, eaeA,* and *hly* virulence genes. The *Stx* production was tested by the Vero cell cytotoxicity assay and a commercial latex agglutination assay. Rat anti-mouse CD47 affinity purified mAb (clone miap301) was obtained from BD Biosciences (San Diego, CA). Anti-human TLR4 and TRAIL antibodies were obtained from Imgenex (San Diego, CA). Inhibitory mouse anti-human CD47 mAb (C5D5) was used as previously described [30]. Mouse Anti-Human CD61 mAb (Clone Y2/51) was obtained from DAKO (Carpinteria, CA).

**Preparation of concentrated culture filtrates (CCF) from STEC**

STEC strains were grown overnight in Trypticase soy broth (Difco Laboratories, Detroit, MI) at 37°C with shaking (180 rpm), supernatants were filtered through 0.22 μm pore-size filters (Millipore) [31], and concentrated to 3-fold higher concentration before used.

**Animal procedure**

6–8 weeks male C57BL6 mice (Jackson Laboratory, Bar Harbor, ME) were housed with free access to water and food in a specific pathogen-free facility. All animal care and handling procedures were carried out in accordance with the National Institute of Health’s Guide for the Care and Use of Laboratory Animals and approved by the Institutional Review Board of Nanjing University, Nanjing, China. Written informed consent was obtained from each participant. Human monocytes, neutrophils (PMNs) and red blood cells (RBCs) were isolated as previously described [32]. To prepare monocyte-derived macrophages (MDMs), isolated monocytes were cultured in DMEM/10% FCS supplemented with macrophage colony-stimulating factor (M-CSF) for 6 days [33]. Mature macrophages (3x10^5/well) were then plated in 24-well tissue culture plates and allowed to adhere for 2 h. After removal of non-adherent cells, the cells were then cultured in DMEM/10% FCS without M-CSF for 24 h before use in phagocytosis assays. All the protocols and procedures were approved by Nanjing University Research Ethics Board.

**Immunofluorescence labeling and flow cytometric analysis**

Blood was collected from a mouse tail vein and was diluted in PBS with 5 mM EDTA. Cells were then incubated with rat anti-CD47 monoclonal antibody (Clone miap301), followed by FITC-conjugated secondary antibody, and phycocerythrin-conjugated anti-mouse CD61 for 30 minutes on ice. After washing off unbound antibody, the samples were analyzed using FACScan flow cytometry and CellQuest software (BD Biosciences). Platelets were distinguished, based on the cell size and CD61 expression.

**Platelet adhesion**

For platelet adhesion, commercial obtained fibrinogen (FBG) and purified SIRPα-GST chimera were immobilized onto 96-well plates prior to adhesion assays. SIRPα-GST chimera and GST protein (served as control) were prepared as previously described [32]. Fluorescently labeled platelets were then added into plates and incubated for 1 h at 37°C. After three washes, fluorescence intensity of each well was measured by a fluorescence plate reader (Molecular Device) and cell adhesion was presented as percentage of total applied cells.

**Phagocytosis of platelets by monocyte-derived macrophages**

Platelets were incubated with anti-platelet CD61 antibody for 20 minutes at room temperature for opsonization. The cells were then washed with HBSS and re-suspended in DMEM/10% FCS. Platelets (3x10^7/per well) were then added, and the plates were centrifuged at 200 g for 1 min to establish contact between macrophages and platelets. Following incubation for 30 min at 37°C under 5% CO₂, the macrophages were washed three times with HBSS. To remove non-ingested platelets, the macrophages were treated with 0.5 mM EDTA and 0.05% trypsin in PBS for 5 min. The ingested platelets by macrophages were analyzed by FV1000 confocal fluorescence microscope equipped with software...
system (Olympus). Percentage of phagocytosis was calculated as the fraction of macrophages with ingested platelets of the total number of macrophages analyzed in 6–8 random selected fields.

Data analysis
Statistical analysis was performed by using Student’s t test for paired samples. All results are expressed as mean±SD. Values of \( p<0.05 \) were considered statistically significant.

Results
In our previous study, an EHEC O157:H7 (strain 99G144) was derived from an outbreak of HUS in Xuzhou, Jiangsu Province, China in 1999. PCR results against four major virulence genes Stx1, Stx2, eaeA and hly have shown that strain 99G144 is a Stx2-eaeA-hly type strain [29]. To assess the ability of STEC O157:H7 (strain 99G144) to induce HUS-like syndrome in animal, we prepared the concentrated culture filtrates (CCF) from culture medium of EHEC strain 99G144 and Shiga toxin-negative O157:H19 (strain 99A041) (served as a control), respectively, and then intraperitoneally injected 0.5 mL/per day of these CCFs into C57BL6 mice. As shown in Figure 1, mice treated with CCF of strain 99G144 had a sharp drop of platelet count on day 4 post-injection compared to mice that injected with saline or strain 99A041 CCF. In addition, significant injury particularly bleeding in multiple organs including kidney, eye and intestine was observed in mice treated with the CCF of strain 99G144 (data not shown). The results implicated that C57BL6 mice treated with STEC O157:H7 CCF suffered a HUS-like symptom.

We next assessed the expression level of CD47 on the surfaces of platelets, neutrophils (PMNs), monocytes, and red blood cells (RBCs), respectively. Surprisingly, we found that, on day 3 post-injection, strain 99G144 CCF treatment strongly decreased CD47 expression on platelet cell surface measured by FACscan flow cytometry (Figure 2A). In contrast, CD47 expression levels on the surfaces of other cell types in mouse circulating blood stream, such as PMNs, monocytes, and RBCs, were not affected by O157:H7 CCF treatment (Figure 2B). Served as a control, treatment with CCF from Shiga toxin-negative O157:H19 (strain 99A041) did not affect platelet surface CD47 expression level.

The effect of STEC O157:H7 CCF on platelet surface CD47 expression was further determined using isolated human platelets. For these experiments, platelets were isolated from peripheral blood of healthy donors, washed with HBSS containing EDTA, and then incubated with CCF from O157:H7 (strain 99G144) or O157:H19 (strain 99A041) at 37°C under 5% CO2. As shown in Figure 3A, platelet surface CD47 expression was reduced by treatment with strain 99G144 CCF but not strain 99A041 CCF, implicating that the component(s) in strain 99G144 CCF can directly interact with platelets and down-regulate platelet CD47 expression. Based on the fact that STEC strain 99G144 is a Stx2-type strain [29] and we did detect significant amount of stx2 in CCF of strain 99G144 but not strain 99A041 (data not shown), the reduction of platelet surface CD47 by STEC strain 99G144 CCF might be partially due to direct interaction between Stx2 and platelets. Since it has been reported that toll like receptors (TLRs) [19] and CD62 [34] were involved in the cytokenia induced by STEC-derived products, we next tested whether TLRs and CD62 play a role in platelet surface CD47 expression and platelet depletion induced by STEC strain 99G144 CCF. As shown in Figure 3B, functional anti-TLR4 antibody strongly blocked the effects of strain 99G144 CCF on platelet surface CD47 expression while anti-CD62 antibody showed no effect. Antibody against TLR9 also reduced the effect of STEC strain 99G144 CCF on the depletion of platelets in C57BL6 mice (Figure 4).

Figure 1. Platelet depletion in C57BL6 mice administered with concentrated culture filtrates (CCF) of STEC O157:H7 (strain 99G144). Note that platelet number was rapidly decreased in mice treated with saline (n=6) or CCF from O157:H19 (strain 99A041) (n=6), *, p<0.05, **, p<0.01.
doi:10.1371/journal.pone.0007131.g001

Figure 2. Reduction of platelet surface CD47 expression in mice treated with CCF from STEC O157:H7 (strain 99G144). A, CD47 expression on platelet surfaces measured by flow cytometry. Cells derived from CD47−/− mice served as a negative control in CD47 immunofluorescence labeling and measurement by flow cytometry. B, CD47 expression levels on the surfaces of platelets (PLT), neutrophils (PMN), monocytes (MO), and red blood cells (RBC), respectively. Shiga toxin-negative strain 99A041 (O157:H19) was used as a control for STEC O157:H7 (strain 99G144). Data were presented as mean±SD of three independent experiments. *, p<0.05.
doi:10.1371/journal.pone.0007131.g002

Figure 3. Platelet depletion in C57BL6 mice administered with concentrated culture filtrates (CCF) of STEC O157:H7 (strain 99G144). Note that platelet number was rapidly decreased in mice treated with saline (n=6) or CCF from O157:H19 (strain 99A041) (n=6), *, p<0.05, **, p<0.01.
doi:10.1371/journal.pone.0007131.g003

Figure 4. Reduction of platelet surface CD47 expression in mice treated with CCF from STEC O157:H7 (strain 99G144). A, CD47 expression on platelet surfaces measured by flow cytometry. Cells derived from CD47−/− mice served as a negative control in CD47 immunofluorescence labeling and measurement by flow cytometry. B, CD47 expression levels on the surfaces of platelets (PLT), neutrophils (PMN), monocytes (MO), and red blood cells (RBC), respectively. Shiga toxin-negative strain 99A041 (O157:H19) was used as a control for STEC O157:H7 (strain 99G144). Data were presented as mean±SD of three independent experiments. *, p<0.05.
doi:10.1371/journal.pone.0007131.g004
platelet surface CD47 expression, albeit at much lower intensity. The results implicated that TLR4-mediated signal pathway might be involved in the modulation of platelet surface CD47 expression by strain 99G144 CCF treatment. This conclusion was also supported by directly treating platelets with lipopolysaccharide (LPS), a TLR4 activating substance [35]. The platelet surface CD47 expression was significantly decreased by LPS treatment (Figure 3B).

To examine the functional status of platelets after treatment with the CCF of STEC O157:H7, isolated human platelets incubated with or without strain 99G144 CCF were further allowed to adhere to 96-well tissue culture plates coated with fibrinogen (FBG) or soluble recombinant of SIRPα extracellular domain (SIRPα-GST). It has been known when platelets are activated, there are more platelets adhere to immobilized FBG [36,37]. As shown in Figure 4A, adhesion of platelets treated with strain 99G144 CCF to immobilized FBG was significantly higher than that of non-treated platelets, suggesting that platelets treated with strain 99G144 CCF were activated. These same platelets treated with strain 99G144 CCF, however, showed a decreased adhesion to immobilized SIRPα-GST recombinant compared to non-treated platelets, confirming that platelets treated with strain 99G144 CCF have less functional SIRPα-binding CD47 on their surfaces (Figure 4B). Together, these results demonstrate that platelets treated with strain 99G144 CCF are in activated form and contain less cell surface CD47.

We next determined the phagocytosis of platelets treated with or without strain 99G144 CCF by human monocyte-derived macrophages (MDMs). Platelets were treated with anti-platelet IgG for opsonization. In separate experiments, incubation was performed in the presence of inhibitory anti-SIRPα antibody or soluble CD47 extracellular domain recombinant (CD47-GST). As shown in Figure 5, after 3 h incubation, phagocytosis of strain 99G144 CCF-treated platelets by MDMs was significantly higher than that of non-treated platelets or platelets treated with strain 99A041 CCF. In fact, internalization of non-treated platelets by MDMs was very low. The enhanced uptake of strain 99G144 CCF-treated platelets by MDMs, however, was abolished by addition of soluble CD47 extracellular domain recombinant. These results argue that down-regulation of CD47 expression level on platelet surfaces is positively correlated with platelet depletion by phagocytes such as macrophages, and that the interactions between platelet CD47 and macrophage SIRPα play a critical role in regulating platelet depletion in STEC infection-induced thrombocytopenia.

Discussion

In the present study, we reported for the first time that platelet surface CD47 reduction is a critical step of platelet depletion in STEC-induced HUS. This conclusion was supported by the data derived from both in vivo and in vitro experiments. First, co-
The occurrence of platelet depletion and down-regulation of platelet surface CD47 was observed in STEC O157:H7 infected mice. Reduction of CD47 expression level was likely specific for platelets since other cells in mouse blood stream had no alteration of surface CD47 after treatment. Second, we confirmed the effect of STEC O157:H7 CCF on reduction of platelet surface CD47 and showed the direct role of STEC strain 99G144 CCF using isolated human platelets. Furthermore, we found that the reduction of platelet surface CD47 expression by strain 99G144 CCF could be blocked by anti-TLRs antibodies, implicating that TLRs-mediated platelet surface CD47 expression by strain 99G144 CCF could be blocked by anti-TLRs antibodies, implicating that TLRs-mediated signaling pathway. CD47 down-regulation on platelet surfaces results in a loss of the negative regulatory mechanism initiated by CD47-SIRPα interactions [21], which in turn, leads to platelet activation and consequent phagocytosis of platelets by macrophages or other SIRPα-positive immune cells. Since soluble CD47 extracellular domain recombinant can block the enhanced phagocytosis of STEC virulent factors-treated platelets by macrophages, CD47 may be a novel therapeutic targets aiming at attenuating and preventing STEC infection-induced platelet depletion.

**Acknowledgments**

We greatly appreciate Dr. Ling Gu (Jiangsu CDC, Nanjing, Jiangsu, China) for providing EHEC O157:H7 (strain 99G144) and Shiga toxin-negative strain (strain 99A041).

**Author Contributions**

Conceived and designed the experiments: CYZ KZ. Performed the experiments: HP HH CW. Analyzed the data: YY CY. Contributed reagents/materials/analysis tools: CYZ. Wrote the paper: KZ.

**References**

1. Karmali MA (1989) Infection by verocytotoxin-producing Escherichia coli. Clin Microbiol Rev 2: 15–38.
2. Karpman D, Papadopoulou D, Nilsson K, Sjogren AC, Mikaelsson C, et al. (2001) Platelet activation by Shiga toxin and circulatory factors as a pathogenic mechanism in the hemolytic uremic syndrome. Blood 97: 3100–3108.
3. Appiani AC, Edelstone A, Bettinelli A, Cassi MM, Paracchini ML, et al. (1982) The relationship between plasma levels of the factor VIII complex and platelet release products (beta-thromboglobulin and platelet factor 4) in children with the hemolytic-uremic syndrome. Clin Nephrol 17: 195–199.
4. Katayama M, Handa M, Araki Y, Ambo H, Kawai Y, et al. (1993) Soluble P-selectin is present in normal circulation and its plasma level is elevated in patients with thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome. Br J Haematol 84: 702–710.
5. Cohen A, Hannigan GE, Williams BR, Lingwood CA (1987) Roles of globotriosyl- and galabiosylceramide in verotoxin binding and high affinity interferon receptor. J Biol Chem 262: 17088–17091.
6. Cooling LJ, Walker KE, Gille T, Koerner TA (1998) Shiga toxin binds human platelets via globotriaosylceramide (Pk antigen) and a novel platelet glycosphingolipid. Infect Immun 66: 4355–4366.
7. Uchida H, Kiyskawa N, Horie H, Fujimoto J, Takeda T (1999) The detection of Shiga toxins in the kidney of a patient with hemolytic uremic syndrome. Pediatr Res 45: 133–137.
8. Obreg T, Del Vecchio PJ, Brown JE, Moran TP, Rowland BM, et al. (1988) Direct cytotoxic action of Shiga toxin on human vascular endothelial cells. Infect Immun 56: 2373–2378.
9. Tesh VL, Samart JE, Perea LP, Shareifin JB, O’Brien AD (1991) Evaluation of the role of Shiga and Shiga-like toxins in mediating direct damage to human vascular endothelial cells. J Infect Dis 164: 334–352.
10. Wadloowski EA, Burris JA, O’Brien AD (1990) Mouse model for colonization and disease caused by enterohemorrhagic Escherichia coli O157:H7. Infect Immun 58: 2438–2445.
11. Karpman D, Connell H, Svensson M, Scheutz F, Alm P, et al. (1997) The role of lipopolysaccharide and Shiga-like toxin in a mouse model of Escherichia coli O157:H7 infection. J Infect Dis 175: 611–620.
12. Sauter KA, Melton-Celsa AR, Larkin K, Trosell ML, O’Brien AD, et al. (2008) Mouse model of hemolytic-uremic syndrome caused by endotoxin-free Shiga toxin 2 (Stx2) and protection from lethal outcome by anti-Stx2 antibody. Infect Immun 76: 4469–4478.
13. Taylor FB, Jr., Tesh VL, DeBault L, Li A, Chang AC, et al. (1999) Characterization of the baboon responses to Shiga-like toxin: descriptive study of a new primate model of toxic responses to Stx-1. Am J Pathol 154: 1285–1299.

14. Beda M, Ito S, Honda M (2004) Hemolytic uremic syndrome induced by lipopolysaccharide and Shiga-like toxin. Pediatr Nephrol 19: 489–499.

15. Rose PE, Armour JA, Williams CE, Hill FG (1985) Verotoxin and neuraminidase induced platelet aggregating activity in plasma: their possible role in the pathogenesis of the haemolytic uraemic syndrome. J Clin Pathol 38: 438–441.

16. te Loo DM, Monnens LA, van Der Velden TJ, Vermeer MA, van Der Velden TJ, Vermeer MA, Preyers F, et al. (2000) Role of CD47 as a marker of self on red blood cells [see comments]. Science 288: 2051–2054.

17. Viisoreanu D, Polanowska-Grabowska R, Suttitanamongkol S, Obrig TG, Gear AR (2000) Human platelet aggregation is not altered by Shiga toxins 1 or 2. Thromb Res 99: 403–410.

18. Nolasco LH, Turner NA, Bernardo A, Tao Z, Cleary TG, et al. (2005) Hemolytic uremic syndrome-associated Shiga toxins promote endothelial-cell secretion and impair ADAMTS13 cleavage of unusually large von Willebrand factor multimers. Blood 106: 4199–4209.

19. Asham R, Speck ER, Kim M, Crosse AR, Bang KW, et al. (2006) Platelet Toll-like receptor expression modulates lipopolysaccharide-induced thrombocytopenia and tumor necrosis factor-alpha production in vivo. Blood 107: 637–641.

20. Lindberg FP, Gresham HD, Schwarz E, Brown EJ (1993) Molecular cloning of an integrin-associated protein: an immunoglobulin family member with multiple membrane-spanning domains implicated in alpha v beta 3-dependent ligand binding. Journal of Cell Biology 123: 483–496.

21. Cardai SJ, McPhillips KA, Frasch SC, Janssen WJ, Staerfeldt A, et al. (2005) Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell 123: 321–334.

22. Tsai RK, Discher DE (2008) Inhibition of “self” engulfment through TLR4 and CD62 and is detected on circulating platelets in patients with hemolytic uraemic syndrome. Blood 108: 167–176.

23. Oldenborg PA, Zheleznyak A, Fang YF, Lagenaur CF, Gresham HD, et al. (2000) Role of CD47 as a marker of self on red blood cells [see comments]. Science 288: 2051–2054.

24. Khanna R, van Roonen N, Saxena RK (2007) Reduced expression of CD47 and in passive immune thrombocytopenia. Blood 105: 3577–3582.

25. Khandelwal S, van Rooijen N, Saxena RK (2007) Reduced expression of CD47 and in passive immune thrombocytopenia. Blood 105: 3577–3582.